TD Cowen analyst Ryan Langston has maintained their bullish stance on HCA stock, giving a Buy rating today.
Ryan Langston has given his Buy rating due to a combination of factors, including HCA Healthcare’s strong financial performance and strategic initiatives. The company reported a significant adjusted EBITDA beat compared to consensus estimates, indicating robust operational efficiency and effective cost management, particularly in labor expenses. Additionally, HCA’s volume growth across various segments, despite mixed surgical volumes, supports the company’s positive outlook on healthcare demand.
Another factor contributing to the Buy rating is HCA’s proactive approach in managing its supply chain and financial commitments. With a substantial portion of its supply expenses under fixed-price contracts and a significant share buyback program underway, HCA demonstrates financial prudence and shareholder value enhancement. Furthermore, the company’s strategic acquisitions and divestitures, along with anticipated capital expenditure increases, underscore its commitment to growth and market positioning.
In another report released today, KeyBanc also maintained a Buy rating on the stock with a $370.00 price target.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is neutral on the stock.